PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Description

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Conditions

Prostate Cancer (Post Prostatectomy)

Talk to us

Study Overview

On this page

Study Details

Study overview

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Condition
Prostate Cancer (Post Prostatectomy)
Intervention / Treatment

-

Contacts and Locations

Orlando

AdventHealth, Orlando, Florida, United States, 32804

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
  • * An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
  • * Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
  • * Patients currently receiving Androgen Deprivation Therapy (ADT).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

AdventHealth,

Study Record Dates

2027-10-10